Vaccinomic approach for novel multi epitopes vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

Table 1 Predicted B cell epitopes, their antigenicity, allergenicity and toxicity from spike S protein and orf1ab polyprotein

Protein	Epitope^a	Start	End	Length	Emini surface accessibility Prediction^b	Kolaskar & Tongaonkar antigenicity Prediction^c	Karplus & Schulz flexibility Prediction^d	Parker hydrophiliciy Prediction^e	Vaxijen antigenicity^f	Allergenicity	Toxicity
Spike S protein	VYDPLQPE	1137	1144	8	1.923	1.082	Flexible	1.65	0.5148	Nonallergen	Nontoxin
orf1ab	SLDTYPSL	2297	2304	8	1173	1066	Flexible	1.25	0.6746	Nonallergen	Nontoxin
	KSVYYTSNP	1533	1541	9	308	1045	Flexible	2.833	0.6523	Nonallergen	Nontoxin
	DASGKPVPY	2924	2932	9	1632	1046	Flexible	3.178	0.6980	Nonallergen	Nontoxin
	VKGLQPSVGPKQ	6600	6611	12	1136	1066	Flexible	2.408	1.0641	Nonallergen	Nontoxin

^aBepipred linear epitope prediction threshold for both proteins was 0.350
^bEmini surface accessibility prediction threshold for both proteins was 1.000
^cKolaskar & tongaonkar antigenicity prediction threshold for spike S protein and orf1ab was 1.041 and 1.044, respectively
^dKarplus & schulz flexibility prediction threshold for spike S protein and orf1ab was 0.993 and 0.988, respectively
^eParker hydrophiliciy prediction threshold for spike S protein and orf1ab was 1.238 and 1.127, respectively
^fVaxijen antigenicity threshold for both proteins was 0.4

ISSN: 1471-2172